QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 0.0001
-- x --
-- x --
-- - --
$ 0.00 - $ 3.36
6,219
na
1.06M
$ 0.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-21-2023 06-30-2023 10-Q
2 05-15-2023 03-31-2023 10-Q
3 03-31-2023 12-31-2022 10-K
4 11-14-2022 09-30-2022 10-Q
5 08-11-2022 06-30-2022 10-Q
6 05-12-2022 03-31-2022 10-Q
7 03-31-2022 12-31-2021 10-K
8 11-15-2021 09-30-2021 10-Q
9 08-10-2021 06-30-2021 10-Q
10 05-11-2021 03-31-2021 10-Q
11 03-23-2021 12-31-2020 10-K
12 11-12-2020 09-30-2020 10-Q
13 08-18-2020 06-30-2020 10-Q
14 06-12-2020 04-30-2020 10-Q
15 03-23-2020 01-31-2020 10-K
16 12-10-2019 10-31-2019 10-Q
17 09-09-2019 07-31-2019 10-Q
18 06-11-2019 04-30-2019 10-Q
19 03-14-2019 01-31-2019 10-K
20 12-07-2018 10-31-2018 10-Q
21 09-10-2018 07-31-2018 10-Q
22 06-08-2018 04-30-2018 10-Q
23 04-26-2018 01-31-2018 10-K
24 12-12-2017 10-31-2017 10-Q
25 09-13-2017 07-31-2017 10-Q
26 06-14-2017 04-30-2017 10-Q
27 04-21-2017 01-31-2017 10-K
28 12-13-2016 10-31-2016 10-Q
29 09-14-2016 07-31-2016 10-Q
30 06-14-2016 04-30-2016 10-Q
31 05-02-2016 01-31-2016 10-K
32 12-15-2015 10-31-2015 10-Q
33 09-14-2015 07-31-2015 10-Q
34 06-12-2015 04-30-2015 10-Q
35 03-30-2015 12-31-2014 10-K
36 11-14-2014 09-30-2014 10-Q
37 08-14-2014 06-30-2014 10-Q
38 05-15-2014 03-31-2014 10-Q
39 03-31-2014 12-31-2013 10-K
40 12-31-2013 09-30-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 timber-pharmaceuticals-inc-files-for-voluntary-chapter-11-bankruptcy-timber-pharmaceuticals-inc-lists-both-assets-and-liabilities-in-range-of-1m-10m

- Court Filing

 timber-pharmaceuticals-says-proposal-to-approve-merger-agreement-was-not-approved-by-a-majority-of-outstanding-shares-of-common-stock-entitled-to-vote-held-special-meeting-to-vote-on-matters-like-adopt-plan-of-merger-with-leo-us-leo-spiny-merger-sub

- SEC Filing

 hc-wainwright--co-downgrades-timber-pharmaceuticals-to-neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Timber Pharmaceuticals (AMEX:TMBR) from Buy to Neutral.

 crude-oil-falls-nikola-shares-plummet

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow t...

 why-super-league-gaming-are-trading-lower-by-around-46-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33.

 dow-tumbles-over-100-points-timber-pharmaceuticals-shares-spike-higher

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 100 points on Monday. The Dow traded dow...

 us-stocks-mostly-higher-nasdaq-jumps-100-points

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. Following the...

 why-timber-pharmaceuticals-stock-is-skyrocketing-today

Timber Pharmaceuticals, Inc. (NYSE: TMBR) has 

 timber-pharmaceuticals-to-present-interim-analyses-from-phase-3-ascend-study-of-tmb-001-in-congenital-ichthyosis

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Abso...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION